Shareholders Approve Hanmi Acquisition Amidst Going Concern Warning

summarizeSummary

Shareholders of Aptose Biosciences have approved the acquisition by Hanmi Pharmaceutical for C$2.41 per share, providing a positive resolution for the financially distressed company.

check_boxKey Events

• Shareholders Approve Acquisition by Hanmi Pharmaceutical

  On March 31, 2026, shareholders approved the definitive arrangement agreement for Hanmi Pharmaceutical to acquire all outstanding common shares for C$2.41 per share. This finalizes the acquisition process initiated on November 18, 2025, and amended on February 23, 2026.

• Substantial Doubt About Going Concern

  The company's financial statements indicate 'substantial doubt' about its ability to continue as a going concern, citing recurring losses, a working capital deficiency of $2.9 million, and a shareholders' deficit of $27.2 million as of December 31, 2025.

• Secured Additional Financing from Hanmi

  Hanmi provided an additional uncommitted facility of up to $11.1 million via a Second Amended Facility Agreement on February 23, 2026, with $4.0 million already advanced by March 27, 2026, crucial for funding ongoing operations.

• Positive Clinical Data for Tuspetinib

  The 10-K highlights positive clinical data for its lead asset, Tuspetinib, in combination therapy for newly diagnosed AML patients, demonstrating high efficacy and MRD-negative remissions, which likely supported the acquisition.

auto_awesomeAnalysis

Aptose Biosciences' shareholders have approved the acquisition by Hanmi Pharmaceutical for C$2.41 per share, a critical development that provides a definitive exit for investors. This approval comes as the company faces substantial doubt about its ability to continue as a going concern, with significant accumulated deficits and negative working capital. The acquisition, along with recent financing from Hanmi, offers a lifeline and a premium to the current stock price, resolving immediate financial uncertainties. While the company's lead asset, Tuspetinib, has shown promising clinical data, the acquisition means its future development will be under Hanmi's control. The delisting from Nasdaq and ongoing TSX review underscore the challenging environment Aptose faced as an independent entity.